NewsBenzingaAbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst Benzinga 2026.10.22 18:17 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Hold on Estee Lauder Cos, Raises Price Target to $109 Zurn Elkay Water Solutions Raises Quarterly Common Stock Dividend From $0.11 To $0.13 Per Share Blackstone CEO Sounds Alarm on AI Supply Crunch: 'Seldom in My Career Have I Seen' Anything Like It Trump Administration Announces Major Investment In American Fertilizer Manufacturing To Strengthen National Security And Support Farmers; Intrepid Potash To Receive $139M In Proposed Financing To Build Sulfate Of Potash Production Site Near Carlsbad... 'Salesforce Customers Brace For New Fees to Use Claude in Its Apps' - The Information PulteGroup CEO Says Americans Are Putting Home Searches On Hold As Mortgage Rates Surge
Trump Administration Announces Major Investment In American Fertilizer Manufacturing To Strengthen National Security And Support Farmers; Intrepid Potash To Receive $139M In Proposed Financing To Build Sulfate Of Potash Production Site Near Carlsbad...
